RecruitingEarly Phase 1NCT05219799

Sex Disparities in Hypoxic Vasodilation and Impact of Obesity


Sponsor

University of Missouri-Columbia

Enrollment

72 participants

Start Date

Mar 14, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this project is to examine key mechanisms contributing to sex-differences in hypoxic vasodilation and the impact of obesity, with particular emphasis on the sympathetic nervous system.


Eligibility

Min Age: 18 YearsMax Age: 45 Years

Plain Language Summary

Simplified for easier understanding

This study investigates how sex differences (male vs. female) affect how blood vessels respond to low oxygen levels (hypoxic vasodilation) and how obesity changes this response. Understanding these differences could lead to better treatments for conditions like high altitude illness and heart disease. You may be eligible if: - You are between 18 and 45 years old - Your BMI is above 18 kg/m² You may NOT be eligible if: - You are pregnant or breastfeeding - You have diagnosed sleep apnea or more than 10 breathing pauses per hour during sleep - You currently smoke or use nicotine products - You have a bleeding disorder or are on anticoagulation therapy - You have any nerve or neurological disease - You have cardiovascular, liver, kidney, or respiratory disease - Your blood pressure is 140/90 mmHg or higher - You have diabetes or polycystic ovarian syndrome - You are taking prescription medications - You are sensitive or allergic to lidocaine Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGPropranolol Hydrochloride

Regional forearm blockade of β-adrenergic receptors at 20 mcg/dL/min via brachial artery catheter during normoxia and hypoxia exposures

DRUGIsoproterenol

Dose response (1, 3, 6, and 12 ng/dL/min) regional infusion to assess β-adrenergic receptor responsiveness

DRUGPhentolamine Mesylate

This infusion will be for 10 min before baseline measurement (12 mcg/dL/min) and continue the infusion at a maintenance rate (5 mcg/dL/min).

DRUGNorepinephrine

Regional forearm infusion at 8 ng/dL/min via brachial artery catheter during normoxia and hypoxia exposures


Locations(1)

University of Missouri

Columbia, Missouri, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05219799


Related Trials